These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 11401008)

  • 41. 5-HT1-like receptor agonists enhance wakefulness.
    Dzoljic MR; Ukponmwan OE; Saxena PR
    Neuropharmacology; 1992 Jul; 31(7):623-33. PubMed ID: 1407402
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Effect of (+/-)-pindolol on the central 5-HT1A receptor by the use of in vivo microdialysis and hippocampal slice preparations].
    Tsuji K
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2002 Jun; 22(3):85-95. PubMed ID: 12166089
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of the 5-HT₆ receptor antagonists SB-399885 and RO-4368554 and of the 5-HT(2A) receptor antagonist EMD 281014 on sleep and wakefulness in the rat during both phases of the light-dark cycle.
    Monti JM; Jantos H
    Behav Brain Res; 2011 Jan; 216(1):381-8. PubMed ID: 20732355
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 5-HT
    Chen XF; Jin ZL; Gong Y; Zhao N; Wang XY; Ran YH; Zhang YZ; Zhang LM; Li YF
    Neuropharmacology; 2018 Aug; 138():1-9. PubMed ID: 29805118
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder.
    Rush AJ; Armitage R; Gillin JC; Yonkers KA; Winokur A; Moldofsky H; Vogel GW; Kaplita SB; Fleming JB; Montplaisir J; Erman MK; Albala BJ; McQuade RD
    Biol Psychiatry; 1998 Jul; 44(1):3-14. PubMed ID: 9646878
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A new antidepressant.
    Glazer WM
    Behav Healthc; 2011 Sep; 31(6):39-40. PubMed ID: 22026116
    [No Abstract]   [Full Text] [Related]  

  • 47. The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder.
    Sahli ZT; Banerjee P; Tarazi FI
    Expert Opin Drug Discov; 2016; 11(5):515-23. PubMed ID: 26971593
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Changes in sleep and wakefulness following 5-HT1A ligands given systemically and locally in different brain regions.
    Bjorvatn B; Ursin R
    Rev Neurosci; 1998; 9(4):265-73. PubMed ID: 9886141
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vilazodone for the treatment of depression.
    Lindsey WT
    Ann Pharmacother; 2011 Jul; 45(7-8):946-53. PubMed ID: 21672888
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sleep-wake and eeg effects following adenosine a1 agonism and antagonism: similarities and interactions with sleep-wake and eeg effects following a serotonin reuptake inhibitor in rats.
    Ursin R; Bjorvatn B
    Sleep Res Online; 1998; 1(3):119-27. PubMed ID: 11382868
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The influence of ipsapirone, a 5-HT1A agonist, on sleep patterns of healthy subjects.
    Driver HS; Flanigan MJ; Bentley AJ; Luus HG; Shapiro CM; Mitchell D
    Psychopharmacology (Berl); 1995 Jan; 117(2):186-92. PubMed ID: 7753966
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vilazodone: another novel atypical antidepressant drug.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2011 Mar; 49(3):19-22. PubMed ID: 21323263
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modulation of serotonergic function in rat brain by VN2222, a serotonin reuptake inhibitor and 5-HT1A receptor agonist.
    Romero L; Celada P; Martín-Ruiz R; Díaz-Mataix L; Mourelle M; Delgadillo J; Hervás I; Artigas F
    Neuropsychopharmacology; 2003 Mar; 28(3):445-56. PubMed ID: 12629524
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Psychopharmacological profile of the selective serotonin reuptake inhibitor, paroxetine: implication of noradrenergic and serotonergic mechanisms.
    Redrobe JP; Bourin M; Colombel MC; Baker GB
    J Psychopharmacol; 1998; 12(4):348-55. PubMed ID: 10065908
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response.
    Blier P; Bergeron R; de Montigny C
    Neuropsychopharmacology; 1997 May; 16(5):333-8. PubMed ID: 9109104
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clarifications on the effects of 5-HT1A agonists and selective 5-HT reuptake inhibitors on the 5-HT system.
    Blier P; de Montigny C
    Neuropsychopharmacology; 1996 Aug; 15(2):213-6. PubMed ID: 8840358
    [No Abstract]   [Full Text] [Related]  

  • 57. Other Antidepressants.
    Schwasinger-Schmidt TE; Macaluso M
    Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder.
    Robinson DS; Kajdasz DK; Gallipoli S; Whalen H; Wamil A; Reed CR
    J Clin Psychopharmacol; 2011 Oct; 31(5):643-6. PubMed ID: 21869687
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Is there a role for 5-HT1A agonists in the treatment of depression?
    Blier P; Ward NM
    Biol Psychiatry; 2003 Feb; 53(3):193-203. PubMed ID: 12559651
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Blunted 5-HT1A-receptor agonist-induced corticotropin and cortisol responses after long-term ipsapirone and fluoxetine administration to healthy subjects.
    Berlin I; Warot D; Legout V; Guillemant S; Schöllnhammer G; Puech AJ
    Clin Pharmacol Ther; 1998 Apr; 63(4):428-36. PubMed ID: 9585797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.